Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.50 |
| ▸ | KDM5A | P29375 | 1/20 | 0.49 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.49 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4155873 | 0.86 | CYP2C19 (0.53) | CYP2C19AKR1B1CA12CA1CA2 | |
| SCHEMBL4670870 | 0.86 | CYP2C19 (0.53) | CYP2C19AKR1B1KDM5AKDM4CKDM5B | |
| SCHEMBL27947884 | 0.84 | SMN1; SMN2 (0.47) | CYP2C19KLKB1KMT2AMEN1CYP19A1 | |
| SCHEMBL10296127 | 0.84 | MAPT (0.53) | CYP2C19AKR1B1CA12CA1CA2 | |
| SCHEMBL4611670 | 0.82 | CES1 (0.50) | CYP2C19AKR1B1KDM5AKDM4CKDM5B | |
| SCHEMBL10590280 | 0.82 | TSHR (0.50) | CYP2C19AKR1B1CA1CA2KLKB1 | |
| SCHEMBL29709490 | 0.80 | CYP19A1 (0.52) | CA1CA2KMT2AMEN1CYP19A1 | |
| SCHEMBL7184197 | 0.80 | FEN1 (0.54) | CYP2C19AKR1B1CA12CA1CA2 | |
| SCHEMBL4674497 | 0.79 | CYP2C19 (0.47) | CYP2C19AKR1B1KDM5AKDM4CKDM5B | |
| SCHEMBL4674501 | 0.79 | CYP2C19 (0.47) | CYP2C19AKR1B1KDM5AKDM4CKDM5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4237008-A2 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | Elucida Oncology, Inc. (US) | 2023-09-06 | — | — | EP | disclosed |
| WO-2022093800-A2 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | ELUCIDA ONCOLOGY, INC. (US) | 2022-05-05 | — | — | WO | disclosed |
| CN-104761557-B | Hexahydro-1H-pyrrolo[3,4-d]pyrimidine compound and preparation method thereof | 河南师范大学 | 2017-02-22 | — | — | CN | disclosed |
| US-8273741-B2 | Imidazo-pyridazinyl compounds and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-09-25 | — | — | US | disclosed |
| US-8044049-B2 | Fused heterocyclic derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-10-25 | — | — | US | disclosed |
| US-8034812-B2 | Imidazopyridazine derivative having kinase inhibitory activity and pharmaceutical agent thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-10-11 | — | — | US | disclosed |
| US-20100273788-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-28 | — | — | US | disclosed |
| US-20100168424-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-07-01 | — | — | US | disclosed |
| US-20090306374-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-10 | — | — | US | disclosed |
| CN-101541801-A | Fused heterocyclic derivative and use thereof | TAKEDA PHARMACEUTICAL (JP) | 2009-09-23 | — | — | CN | disclosed |
| US-20090137595-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-28 | — | — | US | disclosed |
| EP-2049541-A2 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008016192-A2 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-02-07 | — | — | WO | disclosed |
| EP-0603557-B1 | Catalyst compositions and catalytic processes | PHILLIPS PETROLEUM CO (US) | 1997-07-30 | — | — | EP | disclosed |
| US-5461126-A | Process of polymerizing olefins using organonickel catalyst compositions | PHILLIPS PETROLEUM COMPANY (US) | 1995-10-24 | — | — | US | disclosed |
| US-5332708-A | Ethylene polymerization catalyst, organonickel compound and a heterocyclic nitrogen compound | PHILLIPS PETROLEUM COMPANY (US) | 1994-07-26 | — | — | US | disclosed |
| EP-0603557-A1 | Catalyst compositions and catalytic processes | PHILLIPS PETROLEUM COMPANY (US) | 1994-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273788-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | KDR, FLT1, FLT4 | CYP2C19 164/4885AKR1B1 1001/4885KDM5A 953/4885 |
| US-20090137595-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | KDR, FLT1, FLT4 | CYP2C19 164/4885AKR1B1 1001/4885KDM5A 953/4885 |
| US-20090306374-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | KDR, FLT1, FLT4 | CYP2C19 164/4885AKR1B1 1001/4885KDM5A 953/4885 |
| US-20100168424-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | KDR, FLT1, FLT4 | CYP2C19 236/4885AKR1B1 990/4885KDM5A 1028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.